Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Glutamate transporter solute carrier family 1, member 2 (GLT1/EAAT2), a major modulator of glutamate homeostasis in astrocytes, is assessed in post-mortem human brain samples of frontal cortex area 8 in advanced stages of Alzheimer disease (AD) and terminal stages of dementia with Lewy bodies (DLB) in order to gain understanding of astrogliopathy in diseases manifested by dementia. Glial fibrillary acidic protein (GFAP) mRNA expression is significantly increased in AD but not in DLB, whereas GLT1, vesicular glutamate transporter 1 (vGLUT1) and aldehyde dehydrogenase 1 family member 1 (ALDH1L1) are not modified in AD and DLB when compared with controls. GLT1 protein levels are not altered in AD and DLB but GFAP and ALDH1L1 are significantly increased in AD, and GFAP in DLB. As a result, a non-significant decrease in the ratio between GLT1 and GFAP, and between GLT1 and ALDH1L1, is found in both AD and DLB. Double-labeling immunofluorescence and confocal microscopy revealed no visible reduction of GLT1 immunoreactivity in relation to β-amyloid plaques in AD. These data suggest a subtle imbalance between GLT1, and GFAP and ALDH1L1 expression, with limited consequences in glutamate transport.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 2×
“…1 involving the neocortex, phase 2 with additional involvement of the allocortex, phase 3 involving the diencephalic nuclei, striatum, and cholinergic nuclei of the basal forebrain, phase 4 involving several nuclei of the brain stem, and phase 5 with cerebellar involvement (Thal et al., 2002).”
BackgroundMethodBraak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 3×
“NFTs increase in number and distribution from stages I-II to stages V-VI with generalized involvement of the neocortex (Braak and Braak, 1991).”
BackgroundMethodHeterogeneity of astrocytic form and function.
Oberheim, N. A., Goldman, S. A., & Nedergaard, M. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-452-0_3 · Cited by 638
Schulz-Schaeffer, W. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0711-0 · Cited by 627 · cited 2×
“Since synaptic connectivity is reduced in frontal cortex in AD and DLB (Jellinger, 2000; Selkoe, 2002; Hashimoto and Masliah, 2003; Gong and Lippa, 2010; Schulz-Schaeffer, 2010; Ferrer, 2012; de Wilde et al., 2016; Santpere et al., 2017), the possibility of reduced GLT1 expression secondary to decreased synaptic activ…”
BackgroundThe preclinical phase of the pathological process underlying sporadic Alzheimer’s disease
Braak, H., & Del Tredici, K. (2015) · Brain · doi:10.1093/brain/awv236 · Cited by 540
Deficient glutamate tranport is associated with neurodegeneration in Alzheimer's disease
Masliah, E., Hansen, L., Alford, M., Deteresa, R., & Mallory, M. (1996) · Annals of Neurology · doi:10.1002/ana.410400512 · Cited by 476
Lauderback, C. M., Hackett, J. M., Huang, F. F., Keller, J. N., Szweda, L. I., Markesbery, W. R., & Butterfield, D. A. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00451.x · Cited by 464 · cited 2×
“Indirect data point also to functional alterations of glutamate transporters in AD as a result of oxidative damage (Lauderback et al., 2001), altered solubility (Woltjer et al.”
BackgroundBeyond the role of glutamate as a neurotransmitter
Nedergaard, M., Takano, T., & Hansen, A. J. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn916 · Cited by 450 · cited 1×
“Glutamate transporter solute carrier family 1, member 2 (GLT1/EAAT2) expressed in astrocytes regulates glutamate levels at the synapse and plays a cardinal role in preventing excitotoxic neuronal damage in certain neurodegenerative diseases (Nedergaard et al., 2002; Maragakis and Rothstein, 2006).”
BackgroundAstrocyte phenotype in relation to Alzheimer‐type pathology in the ageing brain
Simpson, J. E., Ince, P. G., Lace, G., Forster, G., Shaw, P. J., Matthews, F., Savva, G., Brayne, C., & Wharton, S. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.015 · Cited by 381 · cited 2×
“An inverse relation between increased Glial fibrillary acidic protein (GFAP) and reduced GLT1 is described in AD with disease progression as defined by Braak stage of NFT pathology (Simpson et al., 2010, 2011).”
BackgroundResultPresynaptic regulation of astroglial excitatory neurotransmitter transporter GLT1
Yang, Y., Gozen, O., Watkins, A., Lorenzini, I., Lepore, A., Gao, Y., Vidensky, S., Brennan, J., Poulsen, D., Won Park, J., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.02.010 · Cited by 237 · cited 1×
“GLT1 expression depends on the number of functional synapses under physiological and pathological conditions (Kugler and Schleyer, 2004; Genoud et al., 2006; Yang et al., 2009).”
BackgroundGlutamate transporter variants reduce glutamate uptake in Alzheimer's disease
Scott, H. A., Gebhardt, F. M., Mitrovic, A. D., Vandenberg, R. J., & Dodd, P. R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.008 · Cited by 202
Ferrer, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.005 · Cited by 174 · cited 4×
“Since synaptic connectivity is reduced in frontal cortex in AD and DLB (Jellinger, 2000; Selkoe, 2002; Hashimoto and Masliah, 2003; Gong and Lippa, 2010; Schulz-Schaeffer, 2010; Ferrer, 2012; de Wilde et al., 2016; Santpere et al., 2017), the possibility of reduced GLT1 expression secondary to decreased synaptic activ…”
BackgroundSelf-citationHashimoto, M., & Masliah, E. (2003) · Neurochemical Research · doi:10.1023/a:1026073324672 · Cited by 78 · cited 1×
“Since synaptic connectivity is reduced in frontal cortex in AD and DLB (Jellinger, 2000; Selkoe, 2002; Hashimoto and Masliah, 2003; Gong and Lippa, 2010; Schulz-Schaeffer, 2010; Ferrer, 2012; de Wilde et al., 2016; Santpere et al., 2017), the possibility of reduced GLT1 expression secondary to…”
Background
Cited by
Pajarillo, E., Rizor, A., Lee, J., Aschner, M., & Lee, E. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.002 · Cited by 478
Astrocyte Biomarkers in Alzheimer’s Disease
Carter, S. F., Herholz, K., Rosa-Neto, P., Pellerin, L., Nordberg, A., & Zimmer, E. R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.11.006 · Cited by 355
Excitatory Amino Acid Transporters in Physiology and Disorders of the Central Nervous System
Malik, A. R., & Willnow, T. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225671 · Cited by 170
Microglia and Astrocyte Function and Communication: What Do We Know in Humans?
Garland, E. F., Hartnell, I. J., & Boche, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824888 · Cited by 165
“Aldh1l1 and GFAP were increased in AD, but in patients with dementia with Lewy bodies (DLB), only an Aldh1l1 increase was detected (Garcia-Esparcia et al., 2018), highlighting different pathological mechanisms between the 2 most commons types of dementia (rather than a common mechanism) with a different astrocytic con…”
BackgroundBrain energy metabolism: Astrocytes in neurodegenerative diseases.
Chen, Z., Yuan, Z., Yang, S., Zhu, Y., Xue, M., Zhang, J., & Leng, L. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13982 · Cited by 153
Metadata
- Authors
- Garcia-Esparcia, P., Diaz-Lucena, D., Ainciburu, M., Torrejón-Escribano, B., Carmona, M., Llorens, F., & Ferrer, I.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-04-26
- Volume
- 10
- Pages
- 122-122
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2802803124
- Cited by
- 55
- References
- 14
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.